| 728 | Humans (MeSH) |
| 489 | Female (MeSH) |
| 469 | Male (MeSH) |
| 448 | Spain (epidemiology) |
| 338 | Adult (MeSH) |
| 332 | Middle Aged (MeSH) |
| 330 | Influenza, Human (epidemiology) |
| 329 | Spain (MeSH) |
| 323 | Aged (MeSH) |
| 264 | Adolescent (MeSH) |
| 232 | Influenza, Human (prevention & control) |
| 191 | Child (MeSH) |
| 177 | Child, Preschool (MeSH) |
| 172 | Young Adult (MeSH) |
| 170 | Aged, 80 and over (MeSH) |
| 162 | Infant (MeSH) |
| 121 | Influenza, Human (virology) |
| 120 | Influenza Vaccines (administration & dosage) |
| 114 | Vaccination (statistics & numerical data) |
| 113 | Seasons (MeSH) |
| 108 | Risk Factors (MeSH) |
| 107 | Influenza A Virus, H1N1 Subtype (MeSH) |
| 93 | Pandemics (MeSH) |
| 93 | Cross-Sectional Studies (MeSH) |
| 86 | Prospective Studies (MeSH) |
| 81 | Influenza A Virus, H1N1 Subtype (isolation & purification) |
| 75 | Hospitalization (statistics & numerical data) |
| 73 | Infant, Newborn (MeSH) |
| 68 | Incidence (MeSH) |
| 67 | Influenza Vaccines (immunology) |
| 66 | Case-Control Studies (MeSH) |
| 61 | Time Factors (MeSH) |
| 61 | Animals (MeSH) |
| 59 | Influenza, Human (diagnosis) |
| 58 | Influenza Vaccines (MeSH) |
| 53 | Disease Outbreaks (MeSH) |
| 52 | Retrospective Studies (MeSH) |
| 52 | Influenza, Human (mortality) |
| 51 | Influenza, Human (complications) |
| 50 | Age Factors (MeSH) |
| 46 | Logistic Models (MeSH) |
| 46 | Influenza A Virus, H1N1 Subtype (immunology) |
| 45 | Population Surveillance (MeSH) |
| 43 | Treatment Outcome (MeSH) |
| 42 | Vaccination (MeSH) |
| 41 | Sentinel Surveillance (MeSH) |
| 41 | Pregnancy (MeSH) |
| 40 | Comorbidity (MeSH) |
| 40 | Cohort Studies (MeSH) |
| 39 | Surveys and Questionnaires (MeSH) |
| 39 | Influenza Vaccines (therapeutic use) |
| 39 | Hospitalization (MeSH) |
| 38 | Influenza, Human (drug therapy) |
| 32 | Primary Health Care (MeSH) |
| 32 | Prevalence (MeSH) |
| 30 | Influenza A Virus, H1N1 Subtype (genetics) |
| 30 | Antiviral Agents (therapeutic use) |
| 29 | Respiratory Tract Infections (epidemiology) |
| 28 | Influenza, Human (therapy) |
| 28 | Influenza, Human (immunology) |
| 26 | Socioeconomic Factors (MeSH) |
| 26 | Severity of Illness Index (MeSH) |
| 25 | Influenza A virus (isolation & purification) |
| 25 | Health Knowledge, Attitudes, Practice (MeSH) |
| 25 | Age Distribution (MeSH) |
| 24 | Influenza, Human (transmission) |
| 24 | Attitude of Health Personnel (MeSH) |
| 23 | Patient Acceptance of Health Care (statistics & numerical data) |
| 23 | Odds Ratio (MeSH) |
| 22 | Influenza Vaccines (adverse effects) |
| 21 | Influenza A Virus, H3N2 Subtype (isolation & purification) |
| 21 | History, 20th Century (MeSH) |
| 21 | Health Personnel (MeSH) |
| 20 | Swine (MeSH) |
| 20 | Community-Acquired Infections (epidemiology) |
| 19 | Sex Factors (MeSH) |
| 19 | Phylogeny (MeSH) |
| 18 | Registries (MeSH) |
| 18 | Prognosis (MeSH) |
| 18 | Intensive Care Units (statistics & numerical data) |
| 18 | Influenza, Human (history) |
| 18 | Influenza A Virus, H3N2 Subtype (immunology) |
| 18 | Health Surveys (MeSH) |
| 17 | Respiratory Tract Infections (virology) |
| 17 | Population Surveillance (methods) |
| 17 | Oseltamivir (therapeutic use) |
| 17 | Mortality (MeSH) |
| 17 | Molecular Sequence Data (MeSH) |
| 17 | Influenza, Human (economics) |
| 16 | Virus Diseases (epidemiology) |
| 16 | Vaccination (psychology) |
| 16 | Survival Analysis (MeSH) |
| 16 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
| 16 | Pneumonia, Viral (epidemiology) |
| 16 | Orthomyxoviridae Infections (veterinary) |
| 16 | Influenza, Human (pathology) |
| 16 | Influenza in Birds (epidemiology) |
| 15 | Swine Diseases (epidemiology) |
| 15 | Sensitivity and Specificity (MeSH) |
| 15 | Regression Analysis (MeSH) |
| 15 | Length of Stay (MeSH) |
| 15 | Influenza B virus (isolation & purification) |
| 15 | Influenza A virus (genetics) |
| 15 | Antibodies, Viral (blood) |
| 14 | Seroepidemiologic Studies (MeSH) |
| 14 | Sequence Analysis, DNA (MeSH) |
| 14 | Pneumococcal Vaccines (administration & dosage) |
| 14 | Orthomyxoviridae Infections (epidemiology) |
| 14 | Nasopharynx (virology) |
| 14 | Multivariate Analysis (MeSH) |
| 14 | Models, Statistical (MeSH) |
| 14 | Hospital Mortality (MeSH) |
| 14 | Disease Outbreaks (statistics & numerical data) |
| 14 | Disease Outbreaks (history) |
| 14 | Cause of Death (MeSH) |
| 13 | Swine Diseases (virology) |
| 13 | Influenza A Virus, H3N2 Subtype (MeSH) |
| 13 | Immunization Schedule (MeSH) |
| 13 | Health Personnel (statistics & numerical data) |
| 13 | Health Care Surveys (MeSH) |
| 13 | Disease Outbreaks (prevention & control) |
| 13 | Anti-Bacterial Agents (therapeutic use) |
| 12 | Sex Distribution (MeSH) |
| 12 | Risk Assessment (MeSH) |
| 12 | Risk (MeSH) |
| 12 | Respiratory Syncytial Virus Infections (epidemiology) |
| 12 | Poisson Distribution (MeSH) |
| 12 | Longitudinal Studies (MeSH) |
| 12 | Confidence Intervals (MeSH) |
| 11 | Vaccination Coverage (statistics & numerical data) |
| 11 | Urban Population (MeSH) |
| 11 | Pneumonia (epidemiology) |
| 11 | Influenza Vaccines (economics) |
| 11 | Influenza B virus (MeSH) |
| 11 | Influenza A Virus, H3N2 Subtype (genetics) |
| 11 | Influenza A Virus, H1N1 Subtype (pathogenicity) |
| 11 | Birds (MeSH) |
| 10 | Virus Diseases (virology) |
| 10 | Travel (MeSH) |
| 10 | Temperature (MeSH) |
| 10 | Pregnancy Complications, Infectious (epidemiology) |
| 10 | Practice Guidelines as Topic (MeSH) |
| 10 | Polymerase Chain Reaction (MeSH) |
| 10 | Patient Admission (statistics & numerical data) |
| 10 | Influenza in Birds (virology) |
| 10 | Influenza A virus (MeSH) |
| 10 | Immunization Programs (MeSH) |
| 10 | Epidemics (MeSH) |
| 10 | Emergency Service, Hospital (statistics & numerical data) |
| 10 | Cross Infection (epidemiology) |
| 10 | Bacterial Infections (epidemiology) |
| 10 | Air Pollution (adverse effects) |
| 10 | Acute Disease (MeSH) |
| 9 | Vaccination (trends) |
| 9 | Vaccination (economics) |
| 9 | Respiratory Tract Infections (diagnosis) |
| 9 | Pneumonia, Viral (virology) |
| 9 | Pandemics (statistics & numerical data) |
| 9 | Interviews as Topic (MeSH) |
| 9 | Influenza B virus (immunology) |
| 9 | Influenza A virus (immunology) |
| 9 | Hospitals, University (MeSH) |
| 9 | Health Status (MeSH) |
| 9 | Follow-Up Studies (MeSH) |
| 9 | Data Collection (MeSH) |
| 9 | Coinfection (epidemiology) |
| 8 | Statistics, Nonparametric (MeSH) |
| 8 | Social Class (MeSH) |
| 8 | Respiratory Tract Diseases (epidemiology) |
| 8 | RNA, Viral (genetics) |
| 8 | Pulmonary Disease, Chronic Obstructive (epidemiology) |
| 8 | Public Health (MeSH) |
| 8 | Pneumonia, Pneumococcal (prevention & control) |
| 8 | Outcome Assessment, Health Care (MeSH) |
| 8 | Orthomyxoviridae Infections (virology) |
| 8 | Mortality (trends) |
| 8 | Models, Theoretical (MeSH) |
| 8 | Intensive Care Units (MeSH) |
| 8 | Influenza, Human (microbiology) |
| 8 | Immunization Programs (statistics & numerical data) |
| 8 | Hemagglutinin Glycoproteins, Influenza Virus (genetics) |
| 8 | Hemagglutination Inhibition Tests (MeSH) |
| 8 | Global Health (MeSH) |
| 8 | Electronic Health Records (MeSH) |
| 8 | Cost-Benefit Analysis (MeSH) |
| 8 | Community-Acquired Infections (virology) |
| 8 | Community-Acquired Infections (microbiology) |
| 8 | Attitude to Health (MeSH) |
| 8 | Antiviral Agents (administration & dosage) |
| 7 | Viral Proteins (genetics) |
| 7 | Survival Rate (MeSH) |
| 7 | Respiration, Artificial (MeSH) |
| 7 | Proportional Hazards Models (MeSH) |
| 7 | Patient Acceptance of Health Care (MeSH) |
| 7 | Inpatients (MeSH) |
| 7 | Influenza, Human (MeSH) |
| 7 | Influenza A virus (classification) |
| 7 | Influenza A Virus, H1N1 Subtype (physiology) |
| 7 | Emergency Service, Hospital (MeSH) |
| 7 | Critical Care (statistics & numerical data) |
| 7 | Costs and Cost Analysis (MeSH) |
| 7 | Air Pollutants (adverse effects) |
| 7 | Absenteeism (MeSH) |
| 6 | Viruses (isolation & purification) |
| 6 | Virus Diseases (diagnosis) |
| 6 | Urban Population (statistics & numerical data) |
| 6 | Urban Health (MeSH) |
| 6 | United States (epidemiology) |
| 6 | Smoking (epidemiology) |
| 6 | Self Report (MeSH) |
| 6 | Respiratory Tract Infections (drug therapy) |
| 6 | Respiratory Syncytial Virus, Human (isolation & purification) |
| 6 | Respiration, Artificial (statistics & numerical data) |
| 6 | Real-Time Polymerase Chain Reaction (MeSH) |
| 6 | Primary Health Care (statistics & numerical data) |
| 6 | Pregnancy Complications, Infectious (virology) |
| 6 | Pregnancy Complications, Infectious (prevention & control) |
| 6 | Pneumonia, Bacterial (microbiology) |
| 6 | Pneumonia, Bacterial (epidemiology) |
| 6 | Pneumonia (etiology) |
| 6 | Patient Acceptance of Health Care (psychology) |
| 6 | Pandemics (prevention & control) |
| 6 | Mass Vaccination (statistics & numerical data) |
| 6 | Length of Stay (statistics & numerical data) |
| 6 | Internet (MeSH) |
| 6 | Influenza, Human (psychology) |
| 6 | Influenza, Human (etiology) |
| 6 | Influenza A Virus, H1N1 Subtype (drug effects) |
| 6 | Infection Control (methods) |
| 6 | Immunocompromised Host (MeSH) |
| 6 | Hospitals, University (statistics & numerical data) |
| 6 | Hospitals (MeSH) |
| 6 | Health Promotion (MeSH) |
| 6 | Health Personnel (psychology) |
| 6 | Genotype (MeSH) |
| 6 | Family Characteristics (MeSH) |
| 6 | Europe (epidemiology) |
| 6 | Epidemiological Monitoring (MeSH) |
| 6 | Educational Status (MeSH) |
| 6 | Databases, Factual (MeSH) |
| 6 | Cross Infection (prevention & control) |
| 6 | Cost of Illness (MeSH) |
| 6 | Community-Acquired Infections (prevention & control) |
| 6 | Chronic Disease (MeSH) |
| 6 | Bayes Theorem (MeSH) |
| 6 | Base Sequence (MeSH) |
| 6 | Asthma (epidemiology) |
| 6 | Antiviral Agents (pharmacology) |
| 6 | Air Pollutants (analysis) |
| 5 | Viral Load (MeSH) |
| 5 | Vaccines (administration & dosage) |
| 5 | Vaccine Potency (MeSH) |
| 5 | Tertiary Care Centers (MeSH) |
| 5 | Swine Diseases (microbiology) |
| 5 | Species Specificity (MeSH) |
| 5 | Sequence Alignment (MeSH) |
| 5 | Respiratory Tract Infections (microbiology) |
| 5 | Respiratory Syncytial Virus Infections (virology) |
| 5 | Respiratory Insufficiency (etiology) |
| 5 | ROC Curve (MeSH) |
| 5 | Pulmonary Disease, Chronic Obstructive (therapy) |
| 5 | Program Evaluation (MeSH) |
| 5 | Predictive Value of Tests (MeSH) |
| 5 | Poultry (MeSH) |
| 5 | Pneumonia, Viral (mortality) |
| 5 | Pneumonia, Viral (etiology) |
| 5 | Pneumonia (mortality) |
| 5 | Pneumococcal Vaccines (MeSH) |
| 5 | Pneumococcal Infections (prevention & control) |
| 5 | Pneumococcal Infections (epidemiology) |
| 5 | Patient Compliance (statistics & numerical data) |
| 5 | Patient Admission (MeSH) |
| 5 | Particulate Matter (analysis) |
| 5 | Outpatients (MeSH) |
| 5 | Oseltamivir (pharmacology) |
| 5 | Orthomyxoviridae (isolation & purification) |
| 5 | Occupational Health (MeSH) |
| 5 | Occupational Exposure (MeSH) |
| 5 | Obesity (epidemiology) |
| 5 | Mutation (MeSH) |
| 5 | Motivation (MeSH) |
| 5 | Molecular Epidemiology (MeSH) |
| 5 | Life Style (MeSH) |
| 5 | Influenza, Human (physiopathology) |
| 5 | Influenza Vaccines (pharmacology) |
| 5 | Influenza A Virus, H1N1 Subtype (classification) |
| 5 | Humidity (MeSH) |
| 5 | Hong Kong (epidemiology) |
| 5 | History, 19th Century (MeSH) |
| 5 | Health Services (statistics & numerical data) |
| 5 | Health Behavior (MeSH) |
| 5 | HIV Infections (drug therapy) |
| 5 | Guidelines as Topic (MeSH) |
| 5 | Forecasting (MeSH) |
| 5 | Feces (virology) |
| 5 | Epidemics (statistics & numerical data) |
| 5 | Environmental Monitoring (MeSH) |
| 5 | Drug Utilization (statistics & numerical data) |
| 5 | Drug Utilization (MeSH) |
| 5 | Critical Illness (MeSH) |
| 5 | Community-Acquired Infections (mortality) |
| 5 | Community-Acquired Infections (drug therapy) |
| 5 | Community-Acquired Infections (diagnosis) |
| 5 | Combined Modality Therapy (MeSH) |
| 5 | Coinfection (virology) |
| 5 | Cluster Analysis (MeSH) |
| 5 | Chi-Square Distribution (MeSH) |
| 5 | Cardiovascular Diseases (mortality) |
| 5 | Bird Diseases (epidemiology) |
| 5 | Animals, Wild (MeSH) |
| 5 | Amino Acid Sequence (MeSH) |
| 5 | Algorithms (MeSH) |
| 5 | Adrenal Cortex Hormones (therapeutic use) |
| 5 | APACHE (MeSH) |
| 4 | Workforce (MeSH) |
| 4 | Whooping Cough (prevention & control) |
| 4 | Viruses (classification) |
| 4 | Virus Diseases (veterinary) |
| 4 | Viral Fusion Proteins (genetics) |
| 4 | Vaccination (methods) |
| 4 | Vaccination (adverse effects) |
| 4 | Sulfur Dioxide (adverse effects) |
| 4 | Space-Time Clustering (MeSH) |
| 4 | Sick Leave (statistics & numerical data) |
| 4 | Rural Population (MeSH) |
| 4 | Respiratory Tract Infections (prevention & control) |
| 4 | Pulmonary Disease, Chronic Obstructive (mortality) |
| 4 | Pulmonary Disease, Chronic Obstructive (complications) |
| 4 | Probability (MeSH) |
| 4 | Primary Health Care (methods) |
| 4 | Pregnant Women (MeSH) |
| 4 | Population Dynamics (MeSH) |
| 4 | Pneumonia, Viral (therapy) |
| 4 | Pneumonia, Viral (drug therapy) |
| 4 | Pneumonia, Viral (diagnosis) |
| 4 | Pneumonia, Viral (complications) |
| 4 | Pneumonia, Pneumococcal (epidemiology) |
| 4 | Pilot Projects (MeSH) |
| 4 | Personnel, Hospital (MeSH) |
| 4 | Periodicity (MeSH) |
| 4 | Patient Compliance (MeSH) |
| 4 | Parvoviridae Infections (epidemiology) |
| 4 | Particulate Matter (toxicity) |
| 4 | Particle Size (MeSH) |
| 4 | Orthomyxoviridae (immunology) |
| 4 | Neuraminidase (genetics) |
| 4 | Mutation, Missense (MeSH) |
| 4 | Multiplex Polymerase Chain Reaction (MeSH) |
| 4 | Multicenter Studies as Topic (MeSH) |
| 4 | Lung (pathology) |
| 4 | Linear Models (MeSH) |
| 4 | Inpatients (statistics & numerical data) |
| 4 | Influenzavirus C (isolation & purification) |
| 4 | Influenza, Human (blood) |
| 4 | Influenza in Birds (prevention & control) |
| 4 | Influenza A virus (pathogenicity) |
| 4 | Influenza A Virus, H1N1 Subtype (metabolism) |
| 4 | Infectious Disease Transmission, Professional-to-Patient (prevention & control) |
| 4 | Immunization Programs (organization & administration) |
| 4 | Immunization (statistics & numerical data) |
| 4 | HIV Infections (epidemiology) |
| 4 | HIV Infections (complications) |
| 4 | Geography (MeSH) |
| 4 | Genetic Variation (MeSH) |
| 4 | Evaluation Studies as Topic (MeSH) |
| 4 | Europe (MeSH) |
| 4 | Enzyme-Linked Immunosorbent Assay (veterinary) |
| 4 | Environmental Exposure (adverse effects) |
| 4 | Emigrants and Immigrants (statistics & numerical data) |
| 4 | Emergencies (MeSH) |
| 4 | Disease Progression (MeSH) |
| 4 | Disease Outbreaks (veterinary) |
| 4 | Disease Notification (statistics & numerical data) |
| 4 | Disease Notification (MeSH) |
| 4 | Cross-Over Studies (MeSH) |
| 4 | Cross Infection (virology) |
| 4 | Communicable Diseases (epidemiology) |
| 4 | Communicable Disease Control (MeSH) |
| 4 | Chronic Disease (epidemiology) |
| 4 | Chickens (MeSH) |
| 4 | Cardiovascular Diseases (epidemiology) |
| 4 | Birds (virology) |
| 4 | Bird Diseases (virology) |
| 4 | Biomarkers (blood) |
| 4 | Antigens, Viral (analysis) |
| 4 | Antibodies, Viral (analysis) |
| 4 | Antibodies, Bacterial (blood) |
| 4 | Analysis of Variance (MeSH) |
| 4 | Air Pollution (statistics & numerical data) |
| 3 | Weather (MeSH) |
| 3 | Weaning (MeSH) |
| 3 | Virus Diseases (mortality) |
| 3 | Viral Vaccines (therapeutic use) |
| 3 | Viral Proteins (metabolism) |
| 3 | Viral Proteins (immunology) |
| 3 | Vaccines, Inactivated (administration & dosage) |
| 3 | Vaccination Coverage (MeSH) |
| 3 | Vaccination (standards) |
| 3 | United States (MeSH) |
| 3 | United Kingdom (epidemiology) |
| 3 | United Kingdom (MeSH) |
| 3 | Terminology as Topic (MeSH) |
| 3 | Swine Diseases (diagnosis) |
| 3 | Sweden (epidemiology) |
| 3 | Sus scrofa (MeSH) |
| 3 | Students, Nursing (psychology) |
| 3 | Streptococcus pneumoniae (isolation & purification) |
| 3 | Spain (ethnology) |
| 3 | Smoking (adverse effects) |
| 3 | Smoking (MeSH) |
| 3 | Shock (etiology) |
| 3 | Serotyping (MeSH) |
| 3 | Schools (MeSH) |
| 3 | Salmonella Infections, Animal (epidemiology) |
| 3 | Salmonella (isolation & purification) |
| 3 | Russia (epidemiology) |
| 3 | Risk Assessment (methods) |
| 3 | Rhinovirus (isolation & purification) |
| 3 | Respiratory Tract Infections (mortality) |
| 3 | Respiratory Tract Diseases (mortality) |
| 3 | Respiratory Tract Diseases (etiology) |
| 3 | Respiratory Insufficiency (therapy) |
| 3 | Research Design (MeSH) |
| 3 | Reproducibility of Results (MeSH) |
| 3 | Reassortant Viruses (genetics) |
| 3 | Quality of Life (MeSH) |
| 3 | Pulmonary Disease, Chronic Obstructive (diagnosis) |
| 3 | Public Health Surveillance (MeSH) |
| 3 | Primary Nursing (MeSH) |
| 3 | Pregnant Women (psychology) |
| 3 | Population (MeSH) |
| 3 | Polymerase Chain Reaction (methods) |
| 3 | Poland (epidemiology) |
| 3 | Point-of-Care Systems (MeSH) |
| 3 | Pneumonia, Viral (microbiology) |
| 3 | Pneumonia, Pneumococcal (mortality) |
| 3 | Pneumonia, Bacterial (diagnosis) |
| 3 | Pneumonia (therapy) |
| 3 | Pneumonia (microbiology) |
| 3 | Pneumococcal Infections (microbiology) |
| 3 | Pharynx (virology) |
| 3 | Personnel, Hospital (statistics & numerical data) |
| 3 | Personnel, Hospital (psychology) |
| 3 | Paramyxoviridae Infections (epidemiology) |
| 3 | Pandemics (history) |
| 3 | Pain (etiology) |
| 3 | Oseltamivir (administration & dosage) |
| 3 | Orthomyxoviridae Infections (prevention & control) |
| 3 | Orthomyxoviridae (genetics) |
| 3 | Occupational Diseases (prevention & control) |
| 3 | Nursing Homes (MeSH) |
| 3 | Nurses (statistics & numerical data) |
| 3 | National Health Programs (MeSH) |
| 3 | Mycoplasma pneumoniae (isolation & purification) |
| 3 | Models, Biological (MeSH) |
| 3 | Mice, Inbred BALB C (MeSH) |
| 3 | Mice (MeSH) |
| 3 | Mexico (MeSH) |
| 3 | Meteorological Concepts (MeSH) |
| 3 | Metapneumovirus (isolation & purification) |
| 3 | Meningococcal Infections (epidemiology) |
| 3 | Mass Vaccination (economics) |
| 3 | Lung (virology) |
| 3 | Legionella pneumophila (isolation & purification) |
| 3 | Laboratories (MeSH) |
| 3 | Intensive Care Units (organization & administration) |
| 3 | Influenzavirus C (immunology) |
| 3 | Influenza Vaccines (supply & distribution) |
| 3 | Influenza B virus (genetics) |
| 3 | Influenza A Virus, H5N1 Subtype (MeSH) |
| 3 | Immunologic Deficiency Syndromes (epidemiology) |
| 3 | Immunoassay (methods) |
| 3 | Immunization, Secondary (MeSH) |
| 3 | Hygiene (MeSH) |
| 3 | Hospitals, General (MeSH) |
| 3 | Hospitalization (trends) |
| 3 | Hospitalization (economics) |
| 3 | Hospital Mortality (trends) |
| 3 | Homes for the Aged (MeSH) |
| 3 | Home Care Services (statistics & numerical data) |
| 3 | Hepatitis B Vaccines (administration & dosage) |
| 3 | Hepatitis B (prevention & control) |
| 3 | Hemagglutinins, Viral (genetics) |
| 3 | Hemagglutinin Glycoproteins, Influenza Virus (metabolism) |
| 3 | Hemagglutination Inhibition Tests (veterinary) |
| 3 | Hand Disinfection (MeSH) |
| 3 | Haemophilus influenzae type b (MeSH) |
| 3 | Haemophilus Vaccines (administration & dosage) |
| 3 | Haemophilus Infections (epidemiology) |
| 3 | HIV Infections (immunology) |
| 3 | Genes, Viral (MeSH) |
| 3 | France (epidemiology) |
| 3 | Fluorescent Antibody Technique (MeSH) |
| 3 | Fever (etiology) |
| 3 | European Union (MeSH) |
| 3 | Enzyme-Linked Immunosorbent Assay (MeSH) |
| 3 | Enterovirus Infections (epidemiology) |
| 3 | Efficiency, Organizational (MeSH) |
| 3 | Ecosystem (MeSH) |
| 3 | Early Diagnosis (MeSH) |
